StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

Equities researchers at StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report issued on Tuesday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Trading Up 1.1 %

NYSE BTX opened at $0.25 on Tuesday. The stock’s 50 day moving average is $0.66 and its 200 day moving average is $1.30. Brooklyn ImmunoTherapeutics has a 12 month low of $0.17 and a 12 month high of $10.10. The stock has a market cap of $14.71 million, a PE ratio of -0.11 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.